Cargando…
Efficacy of combination of venetoclax with azacitidine or chemotherapy in refractory/relapse acute leukemias of ambiguous lineage, not otherwise specified
Acute leukemias of ambiguous lineage, not otherwise specified (ALAL-NOS) is a rare type of acute leukemia. Management of relapse/refractory (R/R) patients is still challenging.traditional chemotherapy treatment is not effective. In this paper, we reported 6 R/R patients diagnosed as ALAL-NOS in our...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8447663/ https://www.ncbi.nlm.nih.gov/pubmed/34530914 http://dx.doi.org/10.1186/s40164-021-00239-w |
| _version_ | 1784569066136010752 |
|---|---|
| author | Liu, Kaiqi Li, Yan Qiu, Shaowei Zhou, Chunlin Wei, Shuning Lin, Dong Zhang, Guangji Wei, Hui Wang, Ying Liu, Bingcheng Gong, Xiaoyuan Fang, Qiuyun Song, Yang Wang, Huijun Li, Chengwen Li, Qinghua Wu, Lihua Gong, Benfa Liu, Yuntao Wang, Jianxiang Mi, Yingchang |
| author_facet | Liu, Kaiqi Li, Yan Qiu, Shaowei Zhou, Chunlin Wei, Shuning Lin, Dong Zhang, Guangji Wei, Hui Wang, Ying Liu, Bingcheng Gong, Xiaoyuan Fang, Qiuyun Song, Yang Wang, Huijun Li, Chengwen Li, Qinghua Wu, Lihua Gong, Benfa Liu, Yuntao Wang, Jianxiang Mi, Yingchang |
| author_sort | Liu, Kaiqi |
| collection | PubMed |
| description | Acute leukemias of ambiguous lineage, not otherwise specified (ALAL-NOS) is a rare type of acute leukemia. Management of relapse/refractory (R/R) patients is still challenging.traditional chemotherapy treatment is not effective. In this paper, we reported 6 R/R patients diagnosed as ALAL-NOS in our hospital, who were treated with venetoclax based treatment (venetoclax combining with azacitidine or chemotherapy). All 6 patients achieved CR. Five of the six patients received allo-HSCT, four patients were still alive in CR until the follow-up day. Our data provide preliminary evidence and show that venetoclax based regimens are effective and safety in patients with R/R ALAL-NOS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40164-021-00239-w. |
| format | Online Article Text |
| id | pubmed-8447663 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-84476632021-09-17 Efficacy of combination of venetoclax with azacitidine or chemotherapy in refractory/relapse acute leukemias of ambiguous lineage, not otherwise specified Liu, Kaiqi Li, Yan Qiu, Shaowei Zhou, Chunlin Wei, Shuning Lin, Dong Zhang, Guangji Wei, Hui Wang, Ying Liu, Bingcheng Gong, Xiaoyuan Fang, Qiuyun Song, Yang Wang, Huijun Li, Chengwen Li, Qinghua Wu, Lihua Gong, Benfa Liu, Yuntao Wang, Jianxiang Mi, Yingchang Exp Hematol Oncol Letter to the Editor Acute leukemias of ambiguous lineage, not otherwise specified (ALAL-NOS) is a rare type of acute leukemia. Management of relapse/refractory (R/R) patients is still challenging.traditional chemotherapy treatment is not effective. In this paper, we reported 6 R/R patients diagnosed as ALAL-NOS in our hospital, who were treated with venetoclax based treatment (venetoclax combining with azacitidine or chemotherapy). All 6 patients achieved CR. Five of the six patients received allo-HSCT, four patients were still alive in CR until the follow-up day. Our data provide preliminary evidence and show that venetoclax based regimens are effective and safety in patients with R/R ALAL-NOS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40164-021-00239-w. BioMed Central 2021-09-16 /pmc/articles/PMC8447663/ /pubmed/34530914 http://dx.doi.org/10.1186/s40164-021-00239-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Letter to the Editor Liu, Kaiqi Li, Yan Qiu, Shaowei Zhou, Chunlin Wei, Shuning Lin, Dong Zhang, Guangji Wei, Hui Wang, Ying Liu, Bingcheng Gong, Xiaoyuan Fang, Qiuyun Song, Yang Wang, Huijun Li, Chengwen Li, Qinghua Wu, Lihua Gong, Benfa Liu, Yuntao Wang, Jianxiang Mi, Yingchang Efficacy of combination of venetoclax with azacitidine or chemotherapy in refractory/relapse acute leukemias of ambiguous lineage, not otherwise specified |
| title | Efficacy of combination of venetoclax with azacitidine or chemotherapy in refractory/relapse acute leukemias of ambiguous lineage, not otherwise specified |
| title_full | Efficacy of combination of venetoclax with azacitidine or chemotherapy in refractory/relapse acute leukemias of ambiguous lineage, not otherwise specified |
| title_fullStr | Efficacy of combination of venetoclax with azacitidine or chemotherapy in refractory/relapse acute leukemias of ambiguous lineage, not otherwise specified |
| title_full_unstemmed | Efficacy of combination of venetoclax with azacitidine or chemotherapy in refractory/relapse acute leukemias of ambiguous lineage, not otherwise specified |
| title_short | Efficacy of combination of venetoclax with azacitidine or chemotherapy in refractory/relapse acute leukemias of ambiguous lineage, not otherwise specified |
| title_sort | efficacy of combination of venetoclax with azacitidine or chemotherapy in refractory/relapse acute leukemias of ambiguous lineage, not otherwise specified |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8447663/ https://www.ncbi.nlm.nih.gov/pubmed/34530914 http://dx.doi.org/10.1186/s40164-021-00239-w |
| work_keys_str_mv | AT liukaiqi efficacyofcombinationofvenetoclaxwithazacitidineorchemotherapyinrefractoryrelapseacuteleukemiasofambiguouslineagenototherwisespecified AT liyan efficacyofcombinationofvenetoclaxwithazacitidineorchemotherapyinrefractoryrelapseacuteleukemiasofambiguouslineagenototherwisespecified AT qiushaowei efficacyofcombinationofvenetoclaxwithazacitidineorchemotherapyinrefractoryrelapseacuteleukemiasofambiguouslineagenototherwisespecified AT zhouchunlin efficacyofcombinationofvenetoclaxwithazacitidineorchemotherapyinrefractoryrelapseacuteleukemiasofambiguouslineagenototherwisespecified AT weishuning efficacyofcombinationofvenetoclaxwithazacitidineorchemotherapyinrefractoryrelapseacuteleukemiasofambiguouslineagenototherwisespecified AT lindong efficacyofcombinationofvenetoclaxwithazacitidineorchemotherapyinrefractoryrelapseacuteleukemiasofambiguouslineagenototherwisespecified AT zhangguangji efficacyofcombinationofvenetoclaxwithazacitidineorchemotherapyinrefractoryrelapseacuteleukemiasofambiguouslineagenototherwisespecified AT weihui efficacyofcombinationofvenetoclaxwithazacitidineorchemotherapyinrefractoryrelapseacuteleukemiasofambiguouslineagenototherwisespecified AT wangying efficacyofcombinationofvenetoclaxwithazacitidineorchemotherapyinrefractoryrelapseacuteleukemiasofambiguouslineagenototherwisespecified AT liubingcheng efficacyofcombinationofvenetoclaxwithazacitidineorchemotherapyinrefractoryrelapseacuteleukemiasofambiguouslineagenototherwisespecified AT gongxiaoyuan efficacyofcombinationofvenetoclaxwithazacitidineorchemotherapyinrefractoryrelapseacuteleukemiasofambiguouslineagenototherwisespecified AT fangqiuyun efficacyofcombinationofvenetoclaxwithazacitidineorchemotherapyinrefractoryrelapseacuteleukemiasofambiguouslineagenototherwisespecified AT songyang efficacyofcombinationofvenetoclaxwithazacitidineorchemotherapyinrefractoryrelapseacuteleukemiasofambiguouslineagenototherwisespecified AT wanghuijun efficacyofcombinationofvenetoclaxwithazacitidineorchemotherapyinrefractoryrelapseacuteleukemiasofambiguouslineagenototherwisespecified AT lichengwen efficacyofcombinationofvenetoclaxwithazacitidineorchemotherapyinrefractoryrelapseacuteleukemiasofambiguouslineagenototherwisespecified AT liqinghua efficacyofcombinationofvenetoclaxwithazacitidineorchemotherapyinrefractoryrelapseacuteleukemiasofambiguouslineagenototherwisespecified AT wulihua efficacyofcombinationofvenetoclaxwithazacitidineorchemotherapyinrefractoryrelapseacuteleukemiasofambiguouslineagenototherwisespecified AT gongbenfa efficacyofcombinationofvenetoclaxwithazacitidineorchemotherapyinrefractoryrelapseacuteleukemiasofambiguouslineagenototherwisespecified AT liuyuntao efficacyofcombinationofvenetoclaxwithazacitidineorchemotherapyinrefractoryrelapseacuteleukemiasofambiguouslineagenototherwisespecified AT wangjianxiang efficacyofcombinationofvenetoclaxwithazacitidineorchemotherapyinrefractoryrelapseacuteleukemiasofambiguouslineagenototherwisespecified AT miyingchang efficacyofcombinationofvenetoclaxwithazacitidineorchemotherapyinrefractoryrelapseacuteleukemiasofambiguouslineagenototherwisespecified |